Dr Neil Shastri-Hurst

The hon. Gentleman is absolutely right. There are countless charities that have done a huge amount of work, and what they are doing is making a tangible difference to people’s lives. Sadly, brain tumours remain one of the most challenging forms of cancer. In many instances, outcomes are no better than when I worked as a doctor in neurosurgery almost a decade and a half ago. The less survivable cancers taskforce has highlighted that one-year survival rates for less survivable cancers, which include brain cancers, remain significantly lower than the average across all cancers. Despite advances in medicine, outcomes for many patients have not improved at the pace that we would all wish to see. That is why the concerns raised by the petitioners are so important. Quite rightly, the petition calls for greater investment in research, wider access to whole-genome sequencing and stronger support for innovative treatments. Those are priorities that cannot be ignored any longer. However, before I turn to those challenges, I want to take a moment to acknowledge the progress that has been made. The National Institute for Health and Care Research has established the brain tumour research consortium, which has brought together dozens of organisations to co-ordinate research and is backed by up to £25.5 million of investment. The recently enacted Rare Cancers Act 2026 represents another significant step forward, and I want to commend the hon. Member for Edinburgh South West (Dr Arthur) for his work in bringing that legislation on to the statute book. The establishment of the national speciality lead and a dedicated cancer registry service have the potential to improve co-ordination and data collection and strengthen research. The national cancer plan has recognised rare cancers as a priority area and committed to expanding successful models such as the Tessa Jowell Brain Cancer Mission. Those developments are of course all welcome. As His Majesty’s loyal Opposition, we supported the Rare Cancers Act throughout its passage through Parliament because we recognise that patients with rare cancers deserve the same urgency, focus and ambition as those with more common conditions. However, the reality is that legislation alone does not save lives; the real test is the effectiveness of its implementation. I would therefore be grateful if the Minister could update us on what progress has been made in establishing the new structures required under the Rare Cancers Act. In particular, has the national specialty lead been appointed? When will the rare cancer registry become fully operational? How will success be measured? Patients and families deserve to know when they will begin to see tangible benefits from the legislation that Parliament has passed. The petition also raised important questions about research participation and access to innovation. The Tessa Jowell Brain Cancer Mission highlighted that fewer than 5% of eligible adult brain tumour patients were able to access whole-genome sequencing because of limitations in tissue sampling and biobanking capacity, which is deeply concerning. Genome sequencing has enormous potential to improve the understanding of tumour biology, identify personalised treatment pathways and increase participation in clinical trials. However, opportunities remain unevenly distributed across the country. The Brain Tumour Charity has also highlighted significant variations in infrastructure and staffing across neuro-oncology centres.